Related Experiment Video
Updated: Jun 13, 2026
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis
Vinod S Ramgolam1, Silva Markovic-Plese
1Department of Neurology, University of North Carolina at Chapel Hill, USA.
Endocrine, Metabolic & Immune Disorders Drug Targets
|April 14, 2010
Summary
Interferon-beta (IFNbeta) therapy for relapsing remitting multiple sclerosis (RR MS) suppresses harmful Th17 cells. This treatment modulates immune cells, reducing key inflammatory markers and offering a targeted approach for MS patients.
Area of Science:
- Immunology
- Neuroimmunology
- Cellular and Molecular Medicine
Background:
- Interferon-beta (IFNbeta) is a primary treatment for relapsing remitting multiple sclerosis (RR MS).
- The precise mechanisms of IFNbeta's action in RR MS remain incompletely understood.
- Th17 cells are implicated in the pathogenesis of autoimmune diseases like MS.
Purpose of the Study:
- To elucidate the immunomodulatory mechanisms of IFNbeta in the context of RR MS.
- To investigate the direct and indirect effects of IFNbeta on Th17 cell differentiation and function.
- To identify specific molecular pathways targeted by IFNbeta in MS pathogenesis.
Main Methods:
- Analysis of IFNbeta's effects on dendritic cells (DCs), B-cells, and T-cells.
- Assessment of cytokine production (IL-27, IL-12, IL-1b, IL-23, IL-10) and signaling pathways (STAT1, SOCS3).
- Evaluation of Th17 cell differentiation markers (RORc, IL-17A, CCR6, IL-23R) in naïve T-cells.
Main Results:
- IFNbeta suppresses Th17 cell differentiation through effects on DCs, B-cells, and T-cells.
- IFNbeta induces Th17-suppressive cytokines (IL-27, IL-12) and inhibits Th17-promoting cytokines (IL-1b, IL-23).
- IFNbeta directly inhibits Th17 differentiation markers in T-cells and induces IL-10 production.
Conclusions:
- IFNbeta selectively targets Th17 cell-mediated autoimmune responses in RR MS.
- The findings provide a deeper understanding of IFNbeta's therapeutic mechanisms in multiple sclerosis.
- IFNbeta's immunomodulatory effects offer a promising therapeutic strategy for RR MS by targeting key inflammatory pathways.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...